La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Quantum BioPharma a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Quantum BioPharma..

Quantum BioPharma (NASDAQ:QNTM) Azioni, Catena delle Opzioni

Quantum BioPharma

Quantum BioPharma Ltd is a biopharmaceutical company dedicated to building a portfolio of inventive assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, it is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company maintains a portfolio of strategic investments through its wholly owned subsidiary, which represents loans secured by residential or commercial property.

Quantum Biopharma Ltd. - Class B Subordinate Voting Shares

Quantum BioPharma Ltd

Trading Ideas

JLHL

Julong Holding Shares Halted On Circuit Breaker To The Downside At $5.59/Share

News

IPOs

Julong Holding Opened For Trade At $6.21/Share; IPO Priced At $4/Share On 1.25M Shares

Rumors

CAEP

Cantor Equity Partners III IPO Price Indicating $10.40/Share On 521K Shares; IPO Priced At $10/Share On 24M Shares

Wells Fargo analyst Roger Read maintains Exxon Mobil (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) with a Overweight and raises the price target from $126 to $127.

Price Target

Analyst Ratings

Wells Fargo Maintains Overweight on Exxon Mobil, Raises Price Target to $127

Wells Fargo analyst Roger Read maintains Chevron (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>) with a Overweight and raises the price target from $164 to $165.

Wells Fargo Maintains Overweight on Chevron, Raises Price Target to $165

Stephens &amp; Co. analyst Pooran Sharma reiterates JBS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JBS#NYSE">JBS</a>) with a Overweight and maintains $22 price target.

Reiteration

Stephens & Co. Reiterates Overweight on JBS, Maintains $22 Price Target

Wells Fargo analyst Roger Read maintains BP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BP#NYSE">BP</a>) with a Equal-Weight and raises the price target from $27 to $32.

Wells Fargo Maintains Equal-Weight on BP, Raises Price Target to $32

Cyngn Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYN#NASDAQ">CYN</a>) stock surged on Thursday after the company <a href="https://www.benzinga.com/pressreleases/25/06/n46111877/cyngn-highlights-next-generation-robotics-automation-and-ai-technologies-at-automatica-in-collabor" target="_blank" rel="noopener">announced its partnership</a> with Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) to showcase its autonomous industrial vehicles at Automatica 2025.
Cyngn develops and deploys autonomous vehicle solutions for industrial fleets, primarily in the manufacturing and logistics sectors.
The collaboration highlights how Cyngn is leveraging the Nvidia Isaac robotics platform to power next-generation autonomous vehicle solutions for industrial applications.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/tech/25/06/45903304/xpeng-says-its-new-self-driving-chip-is-3x-more-powerful-than-nvidias-will-power-vw-cars" rel="noreferrer noopener">Xpeng Says Its New Self-Driving Chip Is 3x More Powerful Than Nvidia&#8217;s, Will Power VW Cars</a>
Cyngn was selected among a few robotics innovators using Nvidia Isaac technologies to accelerate safe, scalable autonomy across dynamic, real-world environments.
Automatica 2025 offers a global platform for showcasing how AI-powered solutions are transforming manufacturing and logistics.
Cyngn&#8217;s autonomous industrial vehicles, built on Nvidia Isaac and powered by Cyngn&#8217;s proprietary DriveMod software, are currently operating in commercial environments to reduce labor costs, increase throughput, and improve safety.
Cyngn&nbsp;stock plunged 100% in the last 12 months as it grappled with financial challenges and concerns about its ability to meet Nasdaq&#8217;s minimum bid price requirement. The company missed the revenue and EPS consensus analyst estimates in the last four quarters. It regained Nasdaq compliance in March 2025.
Price Action: CYN stock is up 135.7% at $11.88 premarket as of last check on Thursday. NVDA is up 1.34%.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/tech/25/05/45291092/nxp-unveils-next-gen-radar-chip-to-boost-autonomous-driving-systems-amid-tariff-uncertainty" target="_blank" rel="noreferrer noopener">NXP Unveils Next-Gen Radar Chip To Boost Autonomous Driving Systems</a></li>
</ul>
Photo: Shutterstock

Tech

NVDA

Cyngn Stock Soars 135% After Partnering With Nvidia To Showcase Autonomous Industrial Vehicles

Wells Fargo analyst Chris Carey maintains General Mills (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GIS#NYSE">GIS</a>) with a Equal-Weight and lowers the price target from $55 to $53.

Wells Fargo Maintains Equal-Weight on General Mills, Lowers Price Target to $53

JMP Securities analyst Mitch Germain reiterates Safehold (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAFE#NYSE">SAFE</a>) with a Market Outperform and maintains $32 price target.

SAFE

JMP Securities Reiterates Market Outperform on Safehold, Maintains $32 Price Target

Wells Fargo analyst Aaron Rakers maintains Micron Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) with a Overweight and raises the price target from $150 to $170.

Wells Fargo Maintains Overweight on Micron Technology, Raises Price Target to $170

WIIM

BIAF

bioAffinity Technologies shares are trading higher after the company announced it will present cancer research related to the subject of its recent patent at the RNA Therapeutics Conference.

Wells Fargo analyst Eric Luebchow maintains Equinix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EQIX#NASDAQ">EQIX</a>) with a Overweight and lowers the price target from $1065 to $925.

EQIX

Wells Fargo Maintains Overweight on Equinix, Lowers Price Target to $925

JMP Securities analyst Jonathan Wolleben reiterates Rhythm Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>) with a Market Outperform and maintains $84 price target.

RYTM

JMP Securities Reiterates Market Outperform on Rhythm Pharmaceuticals, Maintains $84 Price Target

Wells Fargo analyst Derek Archila maintains Kymera Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KYMR#NASDAQ">KYMR</a>) with a Overweight and lowers the price target from $57 to $53.

KYMR

Wells Fargo Maintains Overweight on Kymera Therapeutics, Lowers Price Target to $53

Morgan Stanley analyst Roy Campbell maintains Karooooo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KARO#NASDAQ">KARO</a>) with a Overweight and raises the price target from $43 to $53.

KARO

Morgan Stanley Maintains Overweight on Karooooo, Raises Price Target to $53

U.S. stocks were higher, with the Nasdaq Composite gaining around 100 points on Thursday.
Shares of H.B. Fuller Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FUL#NYSE">FUL</a>) rose sharply in Thursday's session after the company reported better-than-expected second-quarter earnings and raised its FY2025 adjusted EPS <a href="https://www.benzinga.com/quote/FUL/earnings">guidance above estimates</a>.
H.B. Fuller reported quarterly earnings of $1.18 per share which beat the analyst consensus estimate of $1.08 per share. The company reported quarterly sales of $898.095 million which missed the analyst consensus estimate of $899.955 million.
H.B. Fuller shares jumped 10.8% to $61.60 on Thursday.
Here are some other big stocks recording gains in today&#8217;s session.
<ul class="wp-block-list">
<li>BlackSky Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKSY#NASDAQ">BKSY</a>) shares jumped 16.5% to $20.12. Canaccord Genuity analyst Austin Moeller maintained BlackSky Technology with a Buy and raised the price target from $14 to $20.</li>
<li>TSS, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSSI#NASDAQ">TSSI</a>) gained 16.5% to $31.68.</li>
<li>Worthington Steel, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WS#NYSE">WS</a>) gained 14.5% to $30.06 as the company reported stronger-than-expected financial results for the fourth quarter.</li>
<li>Rocket Lab Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) climbed 13.5% to $36.72.</li>
<li>LZ Technology Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LZMH#NASDAQ">LZMH</a>) gained 13.1% to $15.15.</li>
<li>Anbio Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NNNN#NASDAQ">NNNN</a>) rose 12.5% to $35.80.</li>
<li>BigBear.ai Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBAI#NYSE">BBAI</a>) gained 12.2% to $5.40.</li>
<li>Circle Internet Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRCL#NYSE">CRCL</a>) surged 11% to $220.66.</li>
<li>VEON Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VEON#NASDAQ">VEON</a>) gained 10.7% to $45.17.</li>
<li>Enphase Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>) shares rose 10.6% to $42.18.</li>
<li>Oscar Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OSCR#NYSE">OSCR</a>) jumped 10% to $21.08.</li>
<li>Planet Labs PBC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PL#NYSE">PL</a>) gained 10% to $5.96.</li>
<li>AeroVironment, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVAV#NASDAQ">AVAV</a>) rose 9.8% to $258.01. AeroVironment recently reported better-than-expected quarterly financial results.</li>
<li>Forward Air Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FWRD#NASDAQ">FWRD</a>) gained 9% to $24.48.</li>
<li>MillerKnoll, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLKN#NASDAQ">MLKN</a>) rose 6% to $18.64 after the company reported better-than-expected quarterly EPS and sales.</li>
<li>Alcoa Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AA#NYSE">AA</a>) gained 5.5% to $29.73.</li>
</ul>
Now Read This:
<ul class="wp-block-list">
<li> <a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/46093486/top-2-utilities-stocks-that-may-fall-off-a-cliff-in-q2">Top 2 Utilities Stocks That May Fall Off A Cliff In Q2</a> </li>
</ul>
Photo via Shutterstock

Intraday Update

Markets

Movers

AVAV

BBAI

BlackSky Technology Inc. Class A Common Stock

BKSY

CRCL

ENPH

FWRD

LZMH

MLKN

NNNN

OSCR

RKLB

TSSI

VEON

H.B. Fuller Posts Better-Than-Expected Earnings, Joins AeroVironment, MillerKnoll And Other Big Stocks Moving Higher On Thursday

XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>) is once again capturing attention as technical signals and fundamental developments point toward a potential bullish breakout. 
With rising institutional involvement and the latest upgrades to the XRP Ledger, traders are closely watching for confirmation of <a href="https://www.benzinga.com/money/ripple-xrp-price-prediction">a trend shift.</a>
<figure class="wp-block-table"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Ticker</td>
<td>Price</td>
<td>Market Cap</td>
<td>7-Day Trend</td>
</tr>
<tr>
<td>XRP</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>)</td>
<td>$2.16</td>
<td>$2.6 billion</td>
<td>+0.4%</td>
</tr>
<tr>
<td>Bitcoin</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>$107,265.47</td>
<td>&nbsp;$2.13 trillion</td>
<td>+2.3%&nbsp;</td>
</tr>
<tr>
<td>Ethereum</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>$2,450.40</td>
<td>&nbsp;$295.9 billion</td>
<td>-3%&nbsp;</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: Crypto analyst Cryptoinsightuk highlighted strong bullish signals on XRP's weekly chart.
If XRP closes the week at or above current levels, it will mark the first bullish engulfing candle at a higher low since its local top in January, often a precursor to a major move.
Both the RSI and Stochastic RSI are close to forming a bullish cross, indicating strengthening momentum. 
A breakout above the descending trendline, around 8% above current price, would confirm the move and set the stage for an aggressive rally.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/search?q=%24XRP&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$XRP</a> weekly showing promising signs. If we close here or above for <a href="https://twitter.com/search?q=%24XRP&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$XRP</a> on the weekly, it will be the first time we&#39;ve seen a Bullish Engulfing candle on a higher low since our local top back in January. This could suggest that we are finishing our recent consolidation /… <a href="https://t.co/gn0eYvyI2O">pic.twitter.com/gn0eYvyI2O</a>
&mdash; Cryptoinsightuk (@Cryptoinsightuk) <a href="https://twitter.com/Cryptoinsightuk/status/1938156880221667798?ref_src=twsrc%5Etfw">June 26, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Rose Premium Signals <a href="https://x.com/VipRoseTr/status/1938180642681811450">echoed</a> this outlook, noting that XRP is pressing against a long-standing descending trendline following a solid bounce from support. 
A breakout would likely trigger a continuation rally, with key price targets at $2.4558 and $2.6549. 
Traders are eyeing a retest entry as an ideal setup.
Community News: Ripple recently <a href="https://ripple.com/insights/unlocking-institutional-access-to-defi-on-the-xrp-ledger/">announced </a>the rollout of a Permissioned DEX on the XRP Ledger, tailored for institutional players seeking DeFi access while maintaining compliance. 
This system allows regulated financial institutions to trade on decentralized infrastructure—using permissioned order books for assets like XRP, stablecoins, and wrapped tokens.
In a major boost to XRP's credibility, the European Central Bank <a href="https://www.ainvest.com/news/xrp-news-today-ecb-selects-xrp-ledger-digital-euro-pilot-program-starting-june-2025-2506/">selected</a> the XRP Ledger for its 12-month Digital Euro pilot beginning in June 2025. 
This highlights XRPL's growing role in digital asset tokenization and real-world settlement solutions across Europe. 
Ripple's infrastructure is set to be a foundational layer in the ECB's exploration of central bank digital currencies (CBDCs).
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46054595/xrp-sheds-10-in-seven-days-so-why-are-traders-still-bullish">XRP Sheds 10% In Seven Days – So Why Are Traders Still Bullish?</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$ETH

$XRP

XRP Stuck Below $2.20: Why Is It Not Moving?

JMP Securities analyst Aaron Hecht upgrades PENN Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PENN#NASDAQ">PENN</a>) from Market Perform to Market Outperform and announces $24 price target.

Upgrades

PENN

JMP Securities Upgrades PENN Entertainment to Market Outperform, Announces $24 Price Target

UBS analyst Ashwani Verma maintains Teva Pharmaceutical Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) with a Buy and lowers the price target from $24 to $23.

TEVA

UBS Maintains Buy on Teva Pharmaceutical Indus, Lowers Price Target to $23

Press Releases

Quantum BioPharma Partners with BitGo to Securely Store its Crypto Currency Assets

Health Care

Quantum BioPharma Receives Ethics Committee Approval for Phase 2 Clinical Trial of FSD202 for Nociplastic Pain in Patients with Idiopathic Mast Cell Activation Syndrome

Quantum Biopharma Licensee Celly Nutrition Retains Leading Audit Firm MNP LLP to Advance Capital Raise and Go-Public Readiness and Changes Name To Unbuzzd Wellness Inc.

Legal

Quantum BioPharma Receives $2.35 Million USD from a Mutually-Agreed Global Legal Settlement with Dr. Raza Bokhari

iNGENū CRO Partners with Quantum BioPharma to Launch Pioneering Australian Clinical Trial for Chronic Nociplastic Pain in MCAS Patients

Quantum BioPharma Clarifies It Has Not Changed Its Name

General

Quantum Biopharma Purchases More Bitcoin (BTC) Bringing the Total Investment in Digital Assets to USD $5,000,000

Dividends

Quantum BioPharma Announces Intention to Declare Special Dividend of Contingent Value Rights (CVRs) Linked to Future Litigation Settlement Proceeds

Quantum BioPharma Announces First Person with Multiple Sclerosis (MS) Scanned in Joint Study with Massachusetts General Hospital

Financing

Quantum BioPharma Licensee Unbuzzd Wellness Inc. Launches $5 Million Reg D Capital Raise to Fund Growth and Path to Possible Initial Public Offering

CSE:QNTM

HUGE

MDCX

QNTM

Comments

Quantum BioPharma

Quantum BioPharma (QNTM) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO